LONDON - In a significant development for cystic fibrosis (CF) treatment, Vertex Pharmaceuticals (Nasdaq: VRTX) announced today that the European Commission (EC) has approved the use of KALYDECO (ivacaftor) for the treatment of infants as young as one month old affected by the disease. This landmark decision constitutes an expansion of the original labeling for KALYDECO, further validating the drug’s potential in the battle against cystic fibrosis.
Cystic Fibrosis is a genetic disorder affecting more than 70,000 people worldwide. It primarily impacts the lungs and digestive system, leading to severe respiratory and digestive problems. The disease is caused due to mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Vertex’s announcement holds transformative implications for a segment of cystic fibrosis patients. As per the EC’s approval, the drug KALYDECO can now be administered to infants as small as a month old bearing any of the following mutations in the CFTR gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.
The approval of KALYDECO for expanded use aligns with Vertex Pharmaceuticals’ broader goal of advancing treatment for cystic fibrosis. They are dedicated to expediting the development of their medicines to treat the underlying cause of cystic fibrosis for all patients, regardless of their age.
As an effective medication, KALYDECO has demonstrated its efficacy by improving breathing, overall growth, and weight gain in children, thus leading to an overall improvement in their quality of life. These positive developments have now unlocked its potential use in a younger demographic.
Vertex Pharmaceuticals’ statement declared today’s approval as an ’important milestone’ for those suffering from cystic fibrosis. Vertex’s commitment towards addressing the medical needs of the global cystic fibrosis community seems unwavering. This decision not only broadens the drug’s application but may also encourage other pharmaceutical companies to invest in similar life-transforming drugs.
In light of the growing demand for effective cystic fibrosis treatments, Vertex Pharmaceuticals’ progress is indeed an indispensable contribution to the medical community. The decision by the European Commission will undoubtedly form a significant chapter in the ever-advancing medication playbook to combat cystic fibrosis.
Comments